Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04151134

Evaluation of Tongue Base MucOsectomy & Step sErial Sectioning — MOSES  

Squamous Cell Carcinoma of the Oropharynx Clinical Trial

Official title:
Evaluation of the Role of Tongue Base MucOsectomy and Step sErial Sectioning in the Management of the Unknown Primary Squamous Cell Cancer in the Head and Neck

Clinical Trial Summary

Squamous cell carcinoma (SCC) is a cancer that originates from the cells lining the body and can spread into the lymph glands and beyond. Some patients first present with an SCC which has moved to the lymph glands of the neck. Clinical examination and imaging investigations are performed to try and identify the site where the cancer has originated. However, if no original site can be identified, then the investigators call these 'cancers of an unknown primary' (CUP) of the head and neck. One region where these cancers could have originated from is the oropharynx. There are two areas in the oropharynx were cancers commonly arise. One area is the palatine tonsils, which can be removed for analysis with an operation called tonsillectomy. The other area is the tissue lining the back of the tongue, known as the tongue base. A relatively new surgical technique called 'tongue base mucosectomy' (TBM) allows removal of this tissue to see if the primary cancer is contained within it. This study will then use a histological method called 'step serial sectioning' (SSS) to look in more detail at the tonsils and tongue base, hoping to increase the detection rate of the primary cancer. Centres performing TBM will be asked to participate. Patients will be asked to consent to their tissue being used for SSS after it has undergone conventional histology. Anonymised samples will be sent to a central laboratory in Newcastle for processing. Other anonymised data regarding the patients' diagnosis and care will be collated. Patients will be asked to complete questionnaires regarding pain and swallowing recovery following surgery. A smaller cohort of patients will also be interviewed as part of a qualitative research process to establish their views on CUP and the acceptability of the above treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04151134
Study type Observational
Source Royal Marsden NHS Foundation Trust
Contact John C Hardman, MBChB
Phone +442073528171?
Email johncharles.hardman@nhs.net
Status Recruiting
Phase
Start date November 1, 2019
Completion date December 1, 2028
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05540899 - Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer Phase 1
Active, not recruiting NCT03669718 - A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC Phase 2
Withdrawn NCT01586182 - Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma Phase 1/Phase 2
Not yet recruiting NCT06380686 - Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Recruiting NCT05119036 - Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma Phase 2
Recruiting NCT04031534 - Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma Phase 2
Not yet recruiting NCT05608369 - Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC Phase 2
Terminated NCT02552550 - Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx
Active, not recruiting NCT04398524 - A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC Phase 2
Recruiting NCT06030440 - De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck Phase 2/Phase 3
Completed NCT01663259 - Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients N/A
Recruiting NCT04104945 - p16+ Oropharyngeal Cancer Radiation Optimization Trial Reducing Elective Treatment Volumes (PROTEcT) N/A
Not yet recruiting NCT05962242 - HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT06061705 - Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies N/A
Active, not recruiting NCT03370276 - Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT06112535 - Prospective Clinical Study to Assess the Safety and Efficacy of Versius, in Transoral Robotic Surgery N/A
Completed NCT01921426 - A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck Phase 1
Completed NCT01181648 - Long-Term Impact of Human Papillomavirus (HPV) on Quality of Life
Recruiting NCT05918510 - Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
Recruiting NCT05894083 - A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) Phase 2